Forsight Vision5's Company Presentation from OIS@ASCRS 2015

1. © ForSight VISION5 2015 1
OIS@ASCRS
April 16, 2015
John Maroney, CEO

2. © ForSight VISION5 2015 2
Helios
TM
Ocular Insert is Designed to Improve Adherence
for IOP-Lowering Medication
 Problem:
– ~50% of Patients on PGAs Have Poor Adherence / Challenges Taking Drops
– Inadequate Adherence  High/Variable IOP  Visual Field Loss
 Our Goal:
– Clinically Relevant IOP-Lowering for 6 Months from a Single Physician-
Administered, Non-Invasive Ocular Insert
– Target NDA submission in 2018.
• Final Data Available from Phase 2 Study
• Phase 3 Program starts Q1-2016
 Financing / Pipeline:
– Raised $38.3MM to date from Well-Known VCs
– Additional Product Candidates in Pipeline

3. © ForSight VISION5 2015 3
VISION5 Target Market: Glaucoma / OHT Patients who
are Non-Adherent or Unable to Take Drops
1Nordstrom, et al. “Persistence and Adherence with Topical Glaucoma Therapy.” Am J Ophthalmol 2005;140:598-606.
2Hennessy AL, Katz J, Covert D, Kelly CA, Suan EP, Speicher MA, Sund NJ, Robin AL. A video study of drop instillation in both
glaucoma and retina patients with visual impairment. Am J Ophthalmol. 2011 Dec;152(6):982-8
The Helios Insert is limited by United States Law to Investigational Use.
Highly-Effective Treatments Exist
 PGA Drops are Standard of Care
 >2 Million Patients in USA Use PGAs
Of Glaucoma Patients,
~60% Cannot Administer
Drops Properly2
Yet <50% Use Them After
One Year1 and are at High
Risk for Vision Loss

4. © ForSight VISION5 2015 4
Strong Market Demand for Product that Addresses
Compliance
Appear to be
Non-Compliant
Appear to be
Compliant
Similar Efficacy as
Timolol
69% 53%
Similar Efficacy as
Prostaglandin
65% 52%
Q: What Percentage of Your Patients Would Benefit from
Using the Ocular Insert?
Source: Online survey conducted by Leerink in January 2015. Percentages are mean of answers for “Glaucoma patients” and
“OHT patients,” which were similar in all cases. Assumes product is applied every 6 months.
Conclusion:
• Simple, Safe & Effective Product would likely have Wide Market
Adoption
Appear to be
Non-Compliant
Similar Efficacy as
Timolol
69%
Slightly Less
Efficacy than
Timolol
65%
N=50 ophthalmologists and 50 optometrists

5. © ForSight VISION5 2015 5
Goal: Provide More Consistent Care
1. Potential to Enhance Adherence to Follow up Visits: Cannot Get
Refills by Phone and Miss Appointments with Helios
 Patient must return to physician for new Insert and evidence
suggests that surveillance at appropriate intervals improves
patient outcomes
2. Sustained Release has Opportunity to Lower Mean IOP and
Reduce IOP Variability due to Intermittent or Poor Compliance
 Scenario: Two patients have mean medicated IOP of 19.5
mmHg at a given time point. Which patient would you prefer:
– Patient A: 19.5 mmHg* every day at that time or
– Patient B: 17 mmHg* when they are taking their
medication half of the time or 22 mmHg when they are
missing a dose at 50% of visits?
• Can Discuss scenario during Panel
*Scenario Criteria: Assumes unmedicated IOP of 24 mmHg. 19.5 mmHg (4.5 mmHg IOP reduction) = slightly less efficacy than timolol
with near-perfect adherence. 17 mmHg (7 mmHg IOP reduction) = PGA-like. 22 mmHg = somewhat washed out of medication /
inconsistent dosing.

6. © ForSight VISION5 2015 6
Lead Product Candidate: ForSight HeliosTM Insert
IOP CONTROL
 Continuous Release
of Bimatoprost
 Ensures Compliance
 Preservative Free
INTUITIVE & DURABLE
 Goal: Eliminate Daily
Drops for Patients on
IOP-Lowering Drops
 Replacement During
Existing, Established
Visit Schedule (~6
Months)
NON-INVASIVE
 Simple, Topical In-
Office Placement
 Comfortable to Wear:
 90-95% Patient
Acceptance*
 High Retention Rates
for Insert
Source: *95% (37 of 39) of patients in Study 305 found Insert acceptably comfortable. 90% in FSV5-002 washout period.
The Helios Insert is limited by United States Law to Investigational Use.

7. © ForSight VISION5 2015 7
Clinical Results

8. © ForSight VISION5 2015 8
Phase 1b Pooled Studies 501/502 – Mid Dose
Sustained IOP-reduction for 3-months Observed (N=36 Subjects)
Source: Goldberg, I. et al, American Academy of Ophthalmology (2014)
3-month duration with Mid Dose:
6.7 mmHg reduction
• Phase 1 High Dose (6 Month) Data Accepted for World Glaucoma Congress 2015
The Helios Insert is limited by United States Law to Investigational Use.

9. © ForSight VISION5 2015 9
Summary: Phase 1 Results
 Supports proof-of-concept that a single High Duration Insert can
provide sustained, clinically relevant IOP-lowering for up to 6 months
 No unanticipated adverse events
– Most frequent AEs:
• Hyperemia appears similar to or better than daily PGA drops
• Mucus slightly elevated
 Provided scientific rationale for primary Phase 2 study (FSV5-002)
evaluating the High Duration ocular insert
The Helios Insert is limited by United States Law to Investigational Use.

10. © ForSight VISION5 2015 10
Phase 2 Study (FSV5-002)
 Demonstrated Sustained IOP-Lowering for 6 Months
 93% of subjects: bilateral primary ocular insert retention through first 3 months
 90% of subjects were comfortable wearing inserts prior to randomization
 Most frequent AEs: Ocular Discharge and Hyperemia
 No reported ocular SAEs in PGA Insert arm
 Data Submitted for Peer Reviewed Presentation / Publication in 2015
Screening
N=169
Randomized
(1:1)
N=130
PGA
Insert
+
Artificial Tears
Placebo
Insert
+
0.5% Timolol
6 months
6 months
The Helios Insert is limited by United States Law to Investigational Use.

11. © ForSight VISION5 2015 11
Lead Product Candidate Development Pathway
Ph 2 Efficacy
LPO
Nov
Ph 2 Extension Study #1
Ph 2 Dose-Ranging
Ph 2 Extension Study #2
Ph 3 Program
FDA review
NDA Filing
2015 2016 2017 20182014
The Helios Insert (Lead Product Candidate) is limited by United States Law to Investigational Use.
2019

12. © ForSight VISION5 2015 12
ForSight VISION5 is Actively Developing Products for
Three Major Indications
 Completed Recruiting Dose-Ranging Study for Lead Product Candidate
 Lead Product Candidate Expected to Start Phase 3 in early 2016
 Programs also Active in Glaucoma (Fixed Combination), Dry Eye, Allergy
2MM
Patients
(USA)
GLAUCOMA
5MM
Patients
(USA)
DRY EYE
300k
Patients
(USA)
ALLERGY

13. © ForSight VISION5 2015 13
Team of Leaders and Experts
ForSight VISION5 Team
John Maroney
Chief Executive Officer; Delphi Ventures, EndoTex, Boston Scientific; CVIS,
Abbott Labs, Oximetrix
Cary Reich, Ph.D.
Chief Technology Officer; Inamed, Baxter, Calhoun Vision and Chiron Vision;
>50 US Patents
Charles Semba, M.D. Chief Medical Officer. Shire, SARcode, Genentech, Stanford
Anne Rubin, MBA Vice President, Marketing. ForSight VISION4, Corventis, Medtronic
Carlos Schuler, Ph.D.
Vice President, Technical Operations. S.E.A. Medical Systems, Incline
Therapeutics, Talima, Anesiva, Nektar Therapeutics; 10 US Patents
Judy Gordon, DVM Lead Regulatory Advisor. Owner, ClinReg Consulting
Co-Founders
Prof. Eugene de Juan, Jr., M.D.
ForSight Labs Founder, Distinguished Chair at UCSF, Professor of Ophthalmology
at Duke, Johns Hopkins and USC; over 200 publications
K. Angela Macfarlane, J.D.
CEO, ForSight Labs and ForSight VISION4, The Foundry, TransVascular, AneuRx,
VidaMed
Medical Advisors / Principal Investigators
Prof. Ivan Goldberg Eye Associates, Sydney, AUS; Phase 1 Principal Investigator
Prof. Kuldev Singh Stanford University
Prof. James Brandt University of California, Davis; Phase 2 Principal Investigator

14. © ForSight VISION5 2014 14
Unique Value
HUGE UNMET NEED in One of Largest
Ophthalmic Markets
COMPELLING RESPONSE in Clinical Feasibility
FIRST-IN-CLASS Product Profile
Drug Component has ESTABLISHED
EFFICACY
Platform for SEVERAL MAJOR Ophthalmic
MARKETS